Literature DB >> 10331087

New insights into dopaminergic receptor function using antisense and genetically altered animals.

D R Sibley1.   

Abstract

Dopaminergic receptors are widespread throughout the central and peripheral nervous systems, where they regulate a variety of physiological, behavioral, and endocrine functions. These receptors are also clinically important drug targets for the treatment of a number of disorders, such as Parkinson's disease, schizophrenia, and hyperprolactinemia. To date, five different dopamine receptor subtypes have been cloned and characterized. Many of these subtypes are pharmacologically similar, making it difficult to selectively stimulate or block a specific receptor subtype in vivo. Thus, the assignment of various physiological or behavioral functions to specific dopamine receptor subtypes using pharmacological tools is difficult. In view of this, a number of investigators have--in order to elucidate functional roles--begun to use highly selective genetic approaches to alter the expression of individual dopamine receptor subtypes in vivo. This review discusses recent studies involving the use of genetic approaches for the study of dopaminergic receptor function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10331087     DOI: 10.1146/annurev.pharmtox.39.1.313

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  36 in total

1.  Essential conservation of D1 mutant phenotype at the level of individual topographies of behaviour in mice lacking both D1 and D3 dopamine receptors.

Authors:  John Y F Wong; Jeremiah J Clifford; Jim S Massalas; Anthony Kinsella; John L Waddington; John Drago
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

Review 2.  Dopamine receptors for every species: gene duplications and functional diversification in Craniates.

Authors:  Stéphane Le Crom; Marika Kapsimali; Pierre-Olivier Barôme; Philippe Vernier
Journal:  J Struct Funct Genomics       Date:  2003

Review 3.  G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Authors:  Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 4.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 5.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

Review 6.  Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface.

Authors:  John L Waddington; Colm O'Tuathaigh; Gerard O'Sullivan; Katsunori Tomiyama; Noriaki Koshikawa; David T Croke
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

7.  Comparative Ultrastructural Analysis of D1 and D5 Dopamine Receptor Distribution in the Substantia Nigra and Globus Pallidus of Monkeys.

Authors:  Michele A Kliem; Jean-Francois Pare; Zafar U Khan; Thomas Wichmann; Yoland Smith
Journal:  Adv Behav Biol       Date:  2009-08-21

Review 8.  ADHD, altered dopamine neurotransmission, and disrupted reinforcement processes: implications for smoking and nicotine dependence.

Authors:  Scott H Kollins; R Alison Adcock
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-02-18       Impact factor: 5.067

Review 9.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

10.  Modulation by chronic antipsychotic administration of PKA- and GSK3β-mediated pathways and the NMDA receptor in rat ventral midbrain.

Authors:  Bo Pan; Chao Deng
Journal:  Psychopharmacology (Berl)       Date:  2019-05-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.